Polymeric diffusion matrix containing estradiol diacetate
AssigneeKey Pharmaceuticals, Inc.
InventorsAlec D. Keith, Wallace Snipes
Life of this patent
Estimating the term…
Abstract
There is disclosed a polymeric diffusion matrix for the sustained release of estradiol diacetate by delivery to a patient requiring uterine wall maintenance or other types of estrogen therapy wherein the matrix comprises a polar plasticizer, polyvinylalcohol, polyvinylpyrrolidone, and a pharmaceutically effective amount of estradiol diacetate.
Claims16
A self-supporting polymeric diffusion matrix for the sustained release of estradiol diacetate in order to deliver said estradiol diacetate to a patient and provide said patient with a uterine wall maintenance effect, said matrix comprising from about 2 to about 60% of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of estradiol diacetate to provide a sustained release of said estradiol diacetate over a prolonged period.
A method for the delivery of estradiol diacetate to a patient to provide said patient with a uterine wall maintenance effect, comprising applying in the vicinity of the cervix of said patient a self-supporting diffusion matrix comprising from about 1 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone and a pharmaceutically effective amount of estradiol diacetate to provide a sustained release of said estradiol diacetate over a prolonged period.
A method for the transdermal delivery of estradiol diacetate to a patient to provide said patient with an increased blood level of estradiol comprising applying to said patient a self supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone and a pharmaceutically effective amount of estradiol diacetate to provide a sustained release of said estradiol diacetate over a prolonged period.
A method for the transdermal delivery of estradiol diacetate to a patient for the treatment or prevention of diseases associated with estradiol deficiency to provide said patient with an increased blood level of estradiol comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone and a pharmaceutically effective amount of estradiol diacetate to provide a sustained release of said estradiol diacetate over a prolonged period.
A method for the intravaginal delivery of estradiol diacetate to a patient for the treatment or prevention of diseases associated with estradiol deficiency to provide said patient with an increased blood level of estradiol comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone and a pharmaceutically effective amount of estradiol diacetate to provide a sustained release of said estradiol over a prolonged period.
Dependencies are inferred from the claim text.